Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Urological malignancies and the proteomic-genomic interface.

R D Unwin1, M A Knowles, P J Selby

  • 1ICRF Cancer Medicine Research Unit, St James's University Hospital, Leeds, UK.

Electrophoresis
|December 28, 1999
PubMed
Summary

Early detection of urological cancers like renal, bladder, and prostate cancer is crucial. Genomic and proteomic studies offer promising new biomarkers for improved diagnosis and treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mass spectrometry-based proteomics reveals the distinct nature of the skin proteomes of photoaged compared to intrinsically aged skin.

International journal of cosmetic science·2019
Same author

Erratum to: Frailty has a stronger association with inflammation than age in older veterans.

Immunity & ageing : I & A·2017
Same author

Frailty has a stronger association with inflammation than age in older veterans.

Immunity & ageing : I & A·2016
Same author

PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.

BMC cancer·2016
Same author

International cancer seminars: a focus on kidney cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Urological malignancies (renal, bladder, prostate cancer) represent 16% of all cancer cases.
  • Poor 5-year survival rates are linked to late diagnosis and metastasis.
  • There is a critical need for early detection markers, prognostic indicators, and therapeutic targets.

Purpose of the Study:

  • To review current progress in genomic and proteomic studies of urological malignancies.
  • To highlight the potential of proteomic technologies in advancing the study of these diseases.
  • To identify novel biomarkers for earlier disease detection, prognosis, and therapy response.

Main Methods:

  • Integration of genomics and proteomics to overcome limitations of individual approaches.

Related Experiment Videos

  • Utilizing advanced molecular biology techniques for identifying tumor-associated changes.
  • Analyzing post-translational modifications to complement mRNA expression data.

    • Main Results:

    • Genomic and proteomic approaches have identified novel genes and cancer-related changes in urological malignancies.
    • Proteomics offers a complementary alternative to genomics, addressing disparities in gene and protein expression.
    • Identification of tumor-associated post-translational modifications provides deeper insights into disease pathogenesis.

    Conclusions:

    • Genomic and proteomic studies are crucial for understanding the pathogenesis of urological malignancies.
    • Proteomic technologies hold significant potential for the clinical management of these cancers.
    • Future research should focus on leveraging these integrated approaches for improved patient outcomes.